High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage

Lack of PRAME Expression in Cutaneous T-Cell Lymphomas

“…PRAME expression has been described in a variety of hematologic malignancies, including both acute and chronic myeloid and lymphocytic leukemias, hairy cell leukemia, Hodgkin’s lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and multiple myeloma. PRAME overexpression in these tumors generally portends a poor prognosis with shorter overall survival and progression-free survival and lower chemotherapeutic response [ 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ]. Some studies have described a favorable prognosis with PRAME overexpression in both acute myeloid and lymphoblastic leukemia in pediatric patients as well as acute myeloid leukemia in adults [ 39 , 40 , 41 , 42 ].…”

“…The CTA family comprises a number of genes whose expression is typically restricted to only male germ cells. These antigens are abnormally re-expressed in a variety of solid and hematologic malignancies [ 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 ]. PRAME overexpression is believed to prevent cell cycle arrest and apoptosis by inhibiting the retinoic acid signaling pathway.…”

“…Many studies have reported that PRAME is a helpful marker to distinguish between malignant melanoma and benign nevi. PRAME overexpression generally portends a poor prognosis with shorter overall survival and progression-free survival [ 22 , 23 , 24 , 25 , 28 , 31 , 32 , 33 , 34 ]. Due to its highly restricted pattern of expression, PRAME has emerged as an attractive target for cancer immunotherapy, in which cytotoxic T lymphocytes are developed to selectively target and eliminate PRAME-positive cancer cells [ 21 , 35 , 36 , 37 , 38 ].…”